Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for CytomX Therapeutics (CTMX) over the last 11 years, with Q3 2025 value amounting to $20.0 million.

  • CytomX Therapeutics' Change in Acquisitions & Divestments fell 3442.84% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.0 million, marking a year-over-year decrease of 4675.17%. This contributed to the annual value of $255.5 million for FY2024, which is 709.09% down from last year.
  • CytomX Therapeutics' Change in Acquisitions & Divestments amounted to $20.0 million in Q3 2025, which was down 3442.84% from $32.5 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Change in Acquisitions & Divestments registered a high of $125.0 million during Q4 2023, and its lowest value of $10.0 million during Q3 2021.
  • Its 5-year average for Change in Acquisitions & Divestments is $61.2 million, with a median of $52.2 million in 2021.
  • In the last 5 years, CytomX Therapeutics' Change in Acquisitions & Divestments tumbled by 8181.75% in 2021 and then skyrocketed by 2500.0% in 2023.
  • Over the past 5 years, CytomX Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $10.0 million in 2021, then surged by 899.8% to $100.0 million in 2022, then increased by 25.0% to $125.0 million in 2023, then crashed by 48.0% to $65.0 million in 2024, then tumbled by 69.23% to $20.0 million in 2025.
  • Its last three reported values are $20.0 million in Q3 2025, $32.5 million for Q2 2025, and $50.5 million during Q1 2025.